Alto Neuroscience, Inc.
ANRO
$2.28
$0.010.44%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 192.04% | 232.72% | 151.19% | 178.52% | 22.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.47% | 94.34% | 101.00% | 99.78% | 45.97% |
| Operating Income | -44.47% | -94.34% | -101.00% | -99.78% | -45.97% |
| Income Before Tax | -35.52% | -83.60% | -85.04% | -84.20% | -46.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.52% | -83.60% | -85.04% | -84.20% | -46.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.52% | -83.60% | -85.04% | -84.20% | -46.59% |
| EBIT | -44.47% | -94.34% | -101.00% | -99.78% | -45.97% |
| EBITDA | -44.40% | -94.34% | -102.24% | -100.83% | -46.34% |
| EPS Basic | 80.90% | 74.52% | 74.45% | 61.37% | -42.44% |
| Normalized Basic EPS | 80.91% | 74.52% | 74.45% | 61.37% | -42.44% |
| EPS Diluted | 80.90% | 74.52% | 74.45% | 61.37% | -42.44% |
| Normalized Diluted EPS | 80.91% | 74.52% | 74.45% | 61.37% | -42.44% |
| Average Basic Shares Outstanding | 609.62% | 620.44% | 624.25% | 376.84% | 2.91% |
| Average Diluted Shares Outstanding | 609.62% | 620.44% | 624.25% | 376.84% | 2.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |